<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long-term population-based survival data detailed by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> subtype are important to measure the overall outcomes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> managements </plain></SENT>
<SENT sid="1" pm="."><plain>We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis on 37,549 hematological <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> (HM) patients whose ages were &gt;15 years, diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries </plain></SENT>
<SENT sid="2" pm="."><plain>These are, to our knowledge, the first unbiased estimates of 10-year net survival in HMs detailed by subtypes </plain></SENT>
<SENT sid="3" pm="."><plain>HMs were classified according to the International Classification of Diseases-<z:hpo ids='HP_0002664'>Oncology</z:hpo> 3 </plain></SENT>
<SENT sid="4" pm="."><plain>Net survival was estimated with the unbiased Pohar-Perme method </plain></SENT>
<SENT sid="5" pm="."><plain>The results are reported by sex and age classes </plain></SENT>
<SENT sid="6" pm="."><plain>The changes of these indicators by periods of diagnosis were tabulated and the trends of the net mortality rates over time since diagnosis graphed </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 5- and 10-year age-standardized net survivals after HMs varied widely from 81 and 76% for classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (CHL) to 18 and 14% for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="8" pm="."><plain>Even in HMs with the most favorable prognoses, the net survival decreased between 5- and 10-year postdiagnosis </plain></SENT>
<SENT sid="9" pm="."><plain>Women had better prognoses than men and age at diagnosis was an unfavorable prognostic factor for most HMs </plain></SENT>
<SENT sid="10" pm="."><plain>In patients &lt;55 years old, the net mortality rate decreased to null values 5-year postdiagnosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 10-year postdiagnosis in CHL, precursor non-<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The prognoses improved for various HMs over the study period </plain></SENT>
<SENT sid="12" pm="."><plain>The obtained unbiased indicators are important to evaluate national <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> plans </plain></SENT>
</text></document>